Objective: Endoscopic dacryocystorhinostomy (DCR) has known advantages over external DCR as a less invasive method without the need of any skin incision. Mitomycin C (MMC), a wound healing inhibitor, was used intraoperatively with the objective of reducing incidence of adhesion and synechiae formation as a postoperative complication leading to failure of the procedure.
INTRODUCTION
The endoscopic approach has several advantages; it provides a better esthetic result with no external scar. It allows a onestage procedure to also correct associated nasal pathology that may be causative. It avoids injury to the medial canthus and/or pathologic scar formation. It preserves the pumping mechanism of the orbicularis oculi muscle. 1 The first report of dacryocystorhinostomy (DCR) was by Caldwellin 1893. Caldwell created a rhinostomy using an intranasal approach by removing a portion of the inferior turbinate and following the nasolacrimal duct to the lacrimal sac and described the operation via the endonasal approach. 2 In 1980 McDonogh and Meiring used the modern nasal endoscopic approach and described improved results. 3 The two most common causes of failure in DCR surgery are closure of the surgically created osteotomy with soft tissue obstruction at the common canaliculus. Antiproliferative agent applied at the osteotomy site may reduce the fibrosis and hence the failure rate. Mitomycin C (MMC) and 5-fluorouracil have been equally successful in this regard. 4 In this prospective randomized study, we aim to identify role of MMC in endonasal endoscopic DCR and to correlate the efficacy of endonasal endoscopic DCR with or without MMC.
MATERIALS AND METHODS
For the present study 60 cases of chronic dacryocystitis were selected and underwent endoscopic DCR at our institution from December 2010 to August 2012. Patients presenting with epiphora and discharge from the eye due to a distal obstruction of nasolacrimal duct were included in the criteria for endoscopic DCR.
Patient included into the study were divided into 2 groups, the control group undergo endonasal DCR and the study group undergo endonasal DCR with local application of MMC.
Patients of proximal duct obstruction, revision cases and patients who did not follow-up for 3 months were excluded from our study.
Operative Procedure
• All procedures were done under local anesthesia/general anesthesia. • Patient's head was tilted 15° upwards and turned to the right of the patient, i.e. toward the surgeon. • A 4 mm, 0 or 30° endoscope was introduced into the nasal cavity and whole of the nasal cavity was visualized. • The mucosa of the lateral nasal wall infiltrated with 2 ml of 2% xylocaine with 1:100,000 adrenaline just anterior to the uncinate process. Postoperative Care
• The nasal pack was removed after 24 hours.
• All patients were given systemic oral antibiotic and analgesics for 5 days. Antibiotic eye drops were advised 6 times daily for 3 days. Nasal decongestant drops were instilled 6 drops 3 times a day for 3 days. • All patients were followed at first week, third week, and third month postoperatively. • Nasal endoscopy with syringing was done in each visit and looked for patency, any crusting, granulations and secretions and were removed. • On the basis of these findings results were classified into patent, partially blocked and completely blocked nasolacrimal duct and compared with each group to evaluate the success rate.
OBSERVATIONS AND RESULTS
All the 60 patients (100%) had epiphora as the main complaint of these, 55 patients had purulent discharge associated with epiphora (Table 1 ). In our study patients were divided with equal sex ratio (1:3.28) with seven males and 23 females in each group. Mean age of control group was 33.43 and that of MMC group was 33.36 (Table 2 ). All patients underwent endoscopic DCR and as shown in Table 3 , both groups had intraoperative hemorrhage in 3.33% patients but hemostasis was achieved at the end of the procedure. Two patients of the control group suffered from wound infection (6.67%) and one patient from the MMC group had similar complaints which were successfully treated with antibiotics. Ten patients (33.3%) of the control group and eight patients of the MMC group had postoperative excessive crusting which were removed at each follow-up. Three (10%) patients of the control group and one (3.33%) patient of MMC group had granulations postoperatively which were seen at regular follow-up. Four (13.33%) patients of the control group and three (10%) patients of the MMC group had synechiae in their nasal cavity (Table 3 ). In our study, patients were followed up on 1st week, 3rd week and 3 months and at 3rd month 83.33% of the patients in control group and 90% of those in MMC group showed complete cure with clear flow of saline into nasal cavity on sac syringing (Table 4) .
DISCUSSION
In the present study success rate of 83.33% in endoscopic DCR without MMC (control group) and 90% in endoscopic DCR with intraoperative MMC group was achieved. No significant difference exists between two groups.
Zilelioglu et al (1998) found that success rate of endoscopic DCR with intraoperative MMC was 77.3% whereas without MMC was 77.8% for ostium size. Hence, there was no difference between two groups regarding ostium size and success rate. 5 Roozitalab et al (2004) said that use of intraoperative MMC in DCR does not change success rate of this procedure. 6 Farahani et al (2008) conducted prospective doubleblind randomized clinical trial and showed that patients with nasolacrimal duct obstruction who underwent endoscopic DCR did not benefit from adjunctive topical application of MMC. 7 Although, clinically there were lesser complications in MMC group as compared to the control group but statistically they were not significant but the results were comparable to the above studies.
CONCLUSION
Utilizing the antifibroblastic activity of MMC in preventing scarring at osteotomy site in endoscopic DCR can go a AIJCR long way in preventing the reblockage and maintaining the postoperative patency of passages. Distinctly minimum success rate have been achieved in patients undergoing DCR with intraoperative MMC as compared to patients undergoing control DCR.
Adjunctive use of a wound healing inhibitor is considered to increase the success rate of endoscopic endonasal DCR. Its intraoperative use seems to be easy and safe. But the study of this limited series shows no benefit in using it and warrants further evaluation in larger numbers having survival studies in future.
